47% in the paclitaxel and trastuzumab arm;P= .83).
However, patients who received T-DM1 reported more favorable outcomes during treatment.
The 3-year IDFS rate for patients who received T-DM1 was 97.8% (95% CI, 96.3%â€“99.3%), which exceeded the protocol-specified rate of 95% to reject the null hypothesis (P= .0001).[146][Level of evidence C1] Results were similar at 5 years.[147] Use ouradvanced clinical trial searchto find NCI-supported cancer clinical trials that are now enrolling patients.
The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria.General informationabout clinical trials is also available.